Event

Katerina Samara

.
F. Hoffmann-La Roche, Ltd./Roche (Hellas) S.A.

Vincent Cottin

PhD, MD
Hopital Louis Pradel, Universite de Lyon;Louis Pradel Hosp, Univ of Lyon;Louis Pradel Hospital and Université Claude Bernard Lyon 1;Louis Pradel Hospital, Claude Bernard University Lyon 1

David J. Lederer

MD, MS
Columbia Univ;Columbia University;Columbia University College of Physicians and Surgeons;Columbia University Medical Center

Michael Kreuter

MD, PhD
Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklin;Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg,

Klaus-Uwe Kirchgaessler

MD
F. Hoffmann-La Roche Ltd.;F. Hoffmann-La Roche, Ltd.

Toby M. Maher

MD, MSc, PhD, FRCP
Imperial College;Imperial College London;Imperial College, London;National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Hare;Royal Brompton and Harefield NHS

Maria Molina-Molina

PhD
University Hospital of Bellvitge, Barcelona, and Centro de Investigación Biomédica en Red Enfermedad

Judit Axmann

.
F. Hoffmann-La Roche, Ltd.

Aryeh Fischer

M.D.
Univ of Colorado Denver;University of Colorado School of Medicine

Tamera Jo. Corte

MBBS, BScM, PhD
National Health and Medical Research Counsel;Royal Prince Alfred Hospital;Royal Prince Alfred Hospital and University of Sydney;Royal Prince Alfred Hospital; University of Sydney

Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: Demographic and Baseline Characteristics